CDXS News and Press, Codexis Inc. From 10/19/22

Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...

Codexis ( NASDAQ: CDXS ) said on Monday it had appointed Kevin Norrett as Chief Operating Officer. Norrett has worked for more than twenty years across commercial, business and corporate development, operations and finance for both established and emerging bi...

REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Rahul Singhvi, Sc.D., to its Board of Directors. Dr. Singhvi is a biotechnology indu...

REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Kevin Norrett as Chief Operating Officer (COO), effective immediately. In this role, Mr. N...

REDWOOD CITY, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the recent hosting of its in-person Protein Engineering Forum from September 12-13, 2022 in San Francisco, C...

Baillie Gifford’s 13F portfolio value decreased from ~$143B to ~$97.51B this quarter. They increased Spotify and Royalty Pharma while decreasing Cloudflare, Petrobras, BeiGene, CBRE Group, Teladoc, and Peloton Interactive. The top three positions are Moderna, Tesla Motors, ...

Codexis, Inc. (CDXS) Q2 2022 Earnings Conference Call August 4, 2022 04:30 PM ET Company Participants Brendan Strong - Argot Partners John Nicols - President and Chief Executive Officer Ross Taylor - Chief Financial Officer Stephen Dilly - Board Member ...

The following slide deck was published by Codexis, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Codexis, Inc. 2022 Q2 - Results - Earnings Call Presentation

Codexis press release ( NASDAQ: CDXS ): Q2 GAAP EPS of -$0.04 beats by $0.10 . Revenue of $38.41M (+50.9% Y/Y) beats by $0.55M . Codexis reiterates its financial guidance for 2022 issued on July 14, 2022, Total revenues are expected to be in the range of $1...

Total Revenue up 51% and Product Revenue up 135% YOY 2022 Total Revenue Guidance of $135M-$141M, Including Product Revenues of $112M-$118M REDWOOD CITY, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enablin...